Clearside Biomedical, Inc.
CLSDQ
$0.95
$0.1215.14%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -56.78% | -44.63% | -55.47% | -79.77% | 248.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.78% | -44.63% | -55.47% | -79.77% | 248.39% |
| Cost of Revenue | -- | 179.58% | 11.83% | -58.03% | -100.00% |
| Gross Profit | -61.94% | -48.94% | -58.42% | -80.75% | 366.28% |
| SG&A Expenses | 8.36% | -2.43% | 2.36% | -0.52% | -3.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.73% | -21.84% | -12.56% | -7.63% | 0.44% |
| Operating Income | 6.84% | 15.18% | -1.69% | -16.25% | 17.84% |
| Income Before Tax | 20.69% | 19.31% | 13.93% | -5.74% | 14.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.45% | 17.17% | 11.89% | -5.74% | 14.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.45% | 17.17% | 11.89% | -5.74% | 14.58% |
| EBIT | 6.84% | 15.18% | -1.69% | -16.25% | 17.84% |
| EBITDA | 7.56% | 16.08% | -0.89% | -15.66% | 18.21% |
| EPS Basic | 25.15% | 26.79% | 24.92% | 10.86% | 26.04% |
| Normalized Basic EPS | 27.22% | 28.66% | 26.63% | 10.86% | 26.04% |
| EPS Diluted | 25.15% | 26.79% | 24.92% | 10.86% | 26.37% |
| Normalized Diluted EPS | 27.22% | 28.66% | 26.63% | 10.86% | 26.04% |
| Average Basic Shares Outstanding | 9.72% | 13.53% | 18.11% | 19.40% | 14.89% |
| Average Diluted Shares Outstanding | 9.72% | 13.53% | 18.11% | 19.40% | 14.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |